Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

21.68
-2.0900-8.79%
Post-market: 21.900.2200+1.01%19:56 EDT
Volume:7.57M
Turnover:166.57M
Market Cap:2.27B
PE:-3.04
High:23.20
Open:23.15
Low:21.36
Close:23.77
52wk High:74.40
52wk Low:10.42
Shares:104.79M
Float Shares:95.17M
Volume Ratio:1.36
T/O Rate:7.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1300
EPS(LYR):-7.1300
ROE:-53.47%
ROA:-11.24%
PB:1.99
PE(LYR):-3.04

Loading ...

Sarepta begins ENDEAVOR Cohort 8 trial of ELEVIDYS with sirolimus in 25 non-ambulant Duchenne patients

Reuters
·
Mar 16

Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 16

Sarepta Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
Mar 13

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

Sarepta Therapeutics Is Maintained at Sell by Citigroup

Dow Jones
·
Mar 10

Sarepta price target raised to $9 from $8 at Citi

TIPRANKS
·
Mar 10

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Benzinga
·
Mar 10

BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

Reuters
·
Mar 07

Sarepta Therapeutics (SRPT) Gets a Hold from Evercore ISI

TIPRANKS
·
Mar 03

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty

TIPRANKS
·
Mar 03

Sarepta Therapeutics Eyes 2026 Reset After Rocky Year

TIPRANKS
·
Mar 03

Stock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts

Stock Track
·
Mar 02

Sarepta price target lowered to $29 from $34 at Wedbush

TIPRANKS
·
Mar 02

Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

Sarepta Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 02

Stock Track | Sarepta Therapeutics Plummets 5.16% Intraday Following Wells Fargo Price Target Cut

Stock Track
·
Feb 28

Sarepta Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 28

Sarepta Therapeutics Announces Call for Applications for the 9TH Annual Route 79, the Duchenne Scholarship Program

THOMSON REUTERS
·
Feb 27

Sarepta price target lowered to $38 from $45 at Wells Fargo

TIPRANKS
·
Feb 27

ETF Daily | IONX Soars 42%; NUGT Gains 5%; SQQQ Rises 4%; Tech Soft, Gold Miners Lead

Tiger Newspress
·
Feb 27